Compare CTS & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTS | ATAI |
|---|---|---|
| Founded | 1896 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1994 | 2025 |
| Metric | CTS | ATAI |
|---|---|---|
| Price | $59.13 | $3.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $15.88 |
| AVG Volume (30 Days) | 215.5K | ★ 6.7M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | ★ 15.87 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $541,318,000.00 | $4,089,000.00 |
| Revenue This Year | $5.55 | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | $101.42 | ★ N/A |
| Revenue Growth | 4.95 | ★ 1227.60 |
| 52 Week Low | $36.03 | $1.66 |
| 52 Week High | $60.82 | $6.73 |
| Indicator | CTS | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 67.96 | 46.94 |
| Support Level | $41.09 | $3.41 |
| Resistance Level | $59.66 | $4.24 |
| Average True Range (ATR) | 2.11 | 0.33 |
| MACD | 0.29 | -0.06 |
| Stochastic Oscillator | 79.12 | 5.90 |
CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEMs) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China, Singapore, the Czech Republic, Taiwan, Denmark, and other countries.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.